Clinical & Pharmaceutical Solutions through Analysis
Where Technology and Solutions Meet

CPSA 2013

Connecting Patients and Subject Numbers Through Analysis

October 7-10, 2013
Sheraton Bucks County Hotel
Langhorne, PA

Session Synopsis

Monday, 4:30 pm - 5:30 pm

Executive Roundtable

Discussion Leader: Timothy Olah, Bristol-Myers Squibb

As of today, at least 20 states have approved the use medicinal marijuana as part of the treatment for ALS, MS, AIDS, cancer, epilepsy, and other afflictions. These approvals are the result of a growing number of patients and advocates demanding a legal and safer means to gain access to this "drug." It is estimated that over 500,000 patients in New Jersey may be eligible to obtain medicinal marijuana. Since all of these patients are also being aggressively treated with traditional drugs, what are the implications of adding medicinal marijuana to their disease management? What types of studies need to be conducted (and by whom) to determine the benefits and/or liabilities of prescribing medicinal marijuana to patients? What are legal restrictions and regulatory guidelines overseeing this burgeoning industry and how will they be enforced and governed? This session will discuss the effect that medicinal marijuana is beginning to have on health care providers and businesses associated with the pharmaceutical industry.

Return to program

CPSA - Where Technology and Solutions Meet

©2013 Milestone Development Services. All rights reserved.